Search 

Crescendo Biologics is a biopharmaceutical company developing conditionally-activated T cell enhancing therapeutics, with a particular focus on CD137 (4-1BB).

The innovative, first and best in class programmes are designed to activate only tumour-specific T cells in the tumour micro-environment and not outside it. This approach is expected to reduce the toxicities experienced with traditional immunotherapies and also to lead to the proliferation of tumour-specific T cells with a broad, long-lasting anti-tumour response.

Crystec Pharma is focused on applying supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies. Applications of our mSAS® (modified Supercritical Anti-Solvent) technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.

Our solutions include the following:

• Crystal and particle engineering

• Stabilisation of therapeutic agents derived from biotechnology

• Polymorph screening

• Improved performance of poorly soluble drugs

• Improved bioavailabilty of small molecules

• Alternative routes of delivery such as inhaled therapy

• Taste masking

• Crystallisation seeds

• Residual solvent elimination